MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy.
Sign Up to like & getrecommendations! Published in 2020 at "Seminars in immunology"
DOI: 10.1016/j.smim.2020.101391
Abstract: Pancreatic cancer (PC) is a highly lethal malignancy with a dismal five-year survival rate. This is due to its asymptomatic nature, lack of reliable biomarkers, poor resectability, early metastasis, and high recurrence rate. Limited efficacies… read more here.
Keywords: muc4; treatment; tumor antigen; immunotherapy ... See more keywords
Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing
Sign Up to like & getrecommendations! Published in 2018 at "International Immunology"
DOI: 10.1093/intimm/dxy006
Abstract: Immunotherapies have led to the successful development of novel therapies for cancer. However, there is increasing concern regarding the adverse effects caused by non-tumor-specific immune responses. Here, we report an effective strategy to generate high-avidity… read more here.
Keywords: cd8 cells; antigen specific; tumor antigen; tumor ... See more keywords
Targeting an alternate Wilms’ tumor antigen 1 peptide bypasses immunoproteasome dependency
Sign Up to like & getrecommendations! Published in 2022 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abg8070
Abstract: Designing effective antileukemic immunotherapy will require understanding mechanisms underlying tumor control or resistance. Here, we report a mechanism of escape from immunologic targeting in an acute myeloid leukemia (AML) patient, who relapsed 1 year after… read more here.
Keywords: tcr; wilms tumor; epitope; tumor antigen ... See more keywords
Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion
Sign Up to like & getrecommendations! Published in 2022 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2021-004309
Abstract: Background Type 1 conventional dendritic cells (cDC1s) are characterized by their ability to induce potent CD8+ T cell responses. In efforts to generate novel vaccination strategies, notably against cancer, human cDC1s emerge as an ideal… read more here.
Keywords: human cdc1s; tumor antigen; xcl1 cc3; cdc1s ... See more keywords
OncoVEXmGM-CSFexpands tumor antigen-specific CD8+ T-cell response in preclinical models
Sign Up to like & getrecommendations! Published in 2023 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-006374
Abstract: Background Checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) have demonstrated clinical efficacy in advanced melanoma, but only a subset of patients with… read more here.
Keywords: cell; csf; oncovexmgm csf; checkpoint ... See more keywords
Abstract LB344: Complement-mediated signaling during cross-presentation of tumor antigen augments T cell responses
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb344
Abstract: Production of complement C3a and C5a locally at the immune synapse by activated dendritic cells (DCs) enhances T cell responses in multiple experimental models. Complement signaling through cognate C3a receptor (C3aR) and C5a receptor (C5aR)… read more here.
Keywords: cell responses; complement; tumor antigen; mice ... See more keywords
Mechanisms by Which Dendritic Cells Present Tumor Microparticle Antigens to CD8+ T Cells
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Immunology Research"
DOI: 10.1158/2326-6066.cir-17-0716
Abstract: Tumor-derived microparticles activate a lysosomal pathway enabling dendritic cell upregulation of costimulatory molecules and presentation of tumor antigens to CD+ T cells. Elucidation of this molecular pathway has clinical implications for the development of improved… read more here.
Keywords: activate lysosomal; tumor antigen; cd8 cells; mechanisms dendritic ... See more keywords
Tumor Antigen Heterogeneity: The “Elephant in the Room” of Adoptive T-cell Therapy for Solid Tumors
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology Research"
DOI: 10.1158/2326-6066.cir-19-0801
Abstract: A major hurdle to the efficacy of adoptive cell therapy and chimeric antigen receptors T-cell therapy is the choice of antigen(s) to target. An article in this issue addresses this by capitalizing on the synergistic… read more here.
Keywords: tumor antigen; antigen heterogeneity; adoptive cell; cell ... See more keywords